Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

DexCom (NASDAQ: DXCM) is not a stock that investors should be rushing to sell. It has a few different opportunities to continue pursuing to generate growth, it has plenty of recurring revenue, and the ...

Dexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S. Glucose is a type of sugar people receive from food, and it's the ...

DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long run.

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

DexCom (DXCM) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected ...

DexCom seems to be growing fairly consistently, and that could continue. But the competition for its segment is getting fiercer by the quarter. The long-term effect of new medicines could potentially ...